2016 Debates and Didactics in Hematology and Oncology

Meeting Overview

On behalf of Drs Sagar Lonial and Suresh Ramalingam, course directors, we are pleased to invite you to the 2016 Debates and Didactics in Hematology and Oncology, to be held in Sea Island, Georgia, on July 27-31, 2016.


This meeting features a comprehensive review into mechanisms of disease and treatments for patients with cancer or blood disorders. Interactive debates and didactic lectures on controversial topics and standards of care offer attendees the opportunity to hear how science and clinical experience supports each point of view. Presentations and discussions will focus on current basic and clinical research, including the use of molecular targeted therapy, immunotherapies, and other novel therapeutic approaches. Participants will be provided with an update on practice-changing data in a practical and interactive format, fostering discussion and impacting clinical outcomes for patients.

Target Audience

This educational activity is intended for hematologists, oncologists, and other allied healthcare professionals interested in the management of hematology and oncology.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Evaluate the risks and benefits of emerging therapies and novel treatment strategies for patients with solid tumors and hematologic malignancies, as well as the practical utility of these approaches based on recent clinical data
  • Apply best practices regarding the treatment of patients with cancer, including integration of novel therapeutic approaches and individualization of care
  • Appropriately integrate multimodality therapy and multidisciplinary care to improve the management of patients with cancer
  • Identify appropriate clinical trials in which to enroll patients with cancer

Fee Information

Registration Fees Before May 22 On or After May 22
Physician/PharmD/PhD $550 $650
Mid-level provider/Nurse $300 $375
Fellows, Residents, Students $25 $40
Pharmaceutical industry representative (non-exhibitor) $800 $1000


For additional information contact Jaye Harden, or 678.892.1353.


Course Directors

  • Sagar Lonial, MD
    Professor and Vice Chair for Medical Affairs
    Department of Hematology and Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia
  • Suresh S. Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Director, Division of Medical Oncology
    Winship Cancer Institute of Emory University
    Atlanta, Georgia

Guest Faculty

  • Kenneth Anderson, MD
    Dana-Farber Cancer Institute
    Boston, Massachusetts
  • James Armitage, MD, FASCO
    University of Nebraska Medical Center
    Omaha, Nebraska
  • Michael Atkins, MD
    Georgetown-Lombardi Comprehensive Cancer Center
    Washington, DC
  • Hagop Kantarjian, MD
    University of Texas MD Anderson Cancer Center
    Houston, Texas
  • Susan O’Brien, MD
    UC Irvine Health
    Chao Family Comprehensive Cancer Center
    Orange, California
  • Bert O’Neil, MD
    Indiana University Simon Cancer Center
    Indianapolis, Indiana

Winship Cancer Institute Faculty

  • Olatunji Alese, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Cletus Arciero, MD, FACS
    Associate Professor, Division of Surgical Oncology, Department of Surgery
    Associate Program Director, Breast Oncology Fellowship
  • Martha Arellano, MD
    Associate Professor, Department of Hematology and Medical Oncology
  • Jonathan Beitler, MD, MBA, FACR, FASTRO
    Professor of Radiation Oncology, Otolaryngology, Hematology and Oncology
    Georgia Research Alliance Cancer Scientist
  • Mehmet Bilen, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Bradley Carthon, MD, PhD
    Assistant Professor, Director of Medical Oncology Inpatient
  • Jonathon Cohen, MD, MS
    Assistant Professor, Department of Hematology and Medical Oncology
  • Ian Crocker, MD, FACR
    Professor and Vice Chairman, Department of Radiation Oncology
  • Walter J. Curran, Jr, MD
    Executive Director of Winship Cancer Institute
    Lawrence W. Davis Professor and Chair of Radiation Oncology
    Group Chairman, NRG Oncology
    Georgia Research Alliance Eminent Scholar and Chair in Cancer Research
  • Bassel El-Rayes, MD
    Professor, Department of Hematology and Medical Oncology
    Associate Director for Clinical Research
    Director of Gastrointestinal Oncology Program
  • Christopher Flowers, MD, MS
    Director of the Emory Lymphoma Program
    Associate Professor, Department of Hematology and Medical Oncology
  • Manila Gaddh, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Keerthi Gogineni, MD, MSHP
    Assistant Professor, Department of Hematology and Medical Oncology
  • Leonard T. Heffner, Jr, MD
    Professor, Department of Hematology and Medical Oncology
  • Ira Horowitz, MD, SM, FACOG, FACS
    Chief Medical Officer and Associate Dean, Clinical Services, Emory University Hospital
    John D. Thompson Professor and Chairman, Department of Gynecology and Obstetrics
    Assistant Dean, Clinical Affairs, Emory University School of Medicine
  • Ashesh Jani, MD, MSEE
    Professor, Department of Radiation Oncology
    Director, Residency Program, Department of Radiation Oncology
  • Anand Jillella, MD
    Professor, Department of Hematology and Medical Oncology
    Associate Director for Community Affairs and Outreach
  • Jonathan Kaufman, MD
    Associate Professor, Department of Hematology and Medical Oncology
  • Christine Kempton, MD, MSc
    Associate Professor, Department of Hematology and Medical Oncology and Department of Pediatrics
    Director, Emory/CHOA Hemophilia Treatment Center
  • H. Jean Khoury, MD, FACP
    R. Randall Rollins Chair in Oncology
    Professor, Department of Hematology and Medical Oncology
    Director, Division of Hematology
  • Fadlo R. Khuri, MD, FACP
    Adjunct Professor of Hematology and Medical Oncology, Emory University
    President and Professor of Internal Medicine, American University of Beirut
  • David Kooby, MD, FACS
    Professor of Surgery
    Chief of Emory Surgery, Northern Arc
  • Ragini Kudchadkar, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Amelia Langston, MD
    Professor and Executive Vice Chair, Hematology and Medical Oncology
    Director and Section Chief, Bone Marrow Transplant Program
  • David Lawson, MD
    Professor, Department of Hematology and Medical Oncology
    Co-Chair, Emory Melanoma and Pigmented Lesion Center
  • Mary Jo Lechowicz, MD
    Associate Professor and Vice Chair for Education, Department of Hematology and Medical Oncology
    Margaret H. Rollins Chair in Cancer
  • Viraj Master, MD, PhD, FACS
    Professor, Department of Urology
    Director of Clinical Research, Department of Urology
  • Jane Meisel, MD
    Assistant Professor of Medicine, Department of Hematology and Medical Oncology
  • Ajay K. Nooka, MD, MPH, FACP
    Assistant Professor, Division of Bone Marrow Transplant
  • Taofeek Owonikoko, MD, PhD
    Associate Professor, Department of Hematology and Medical Oncology
  • Elsa Paplomata, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Rathi Pillai, MD
    Assistant Professor, Department of Hematology and Medical Oncology
  • Nabil Saba, MD, FACP
    Professor, Department of Hematology and Medical Oncology
    Chief of Head and Neck Oncology
  • Juan Sarmiento, MD, FACS
    Associate Professor, Division of General and GI Surgery
    Director of Hepatopancreatic Biliary Surgery
  • Charles Staley, MD
    Holland M. Ware Professor of Surgery
    Professor and Chief, Division of Surgical Oncology
    Chief Quality Officer
  • Mylin Torres, MD
    Associate Professor, Department of Radiation Oncology
    Director, Glenn Family Breast Center
  • Elliott Winton, MD
    Professor, Department of Hematology and Medical Oncology
  • Melinda Yushak, MD, MPH
    Assistant Professor, Department of Hematology and Medical Oncology

AGENDA

Thursday    Lung Cancer/Head and Neck Cancer/Lymphoma


  • 07.30 Primer on immune treatments and mechanisms
    Rathi Pillai, MD
  • 07.55 Debate 1—Should PDL-1 testing be used to select patients for immunotherapy in advanced non-small cell lung cancer (NSCLC)?
    Yes: Rathi Pillai, MD
    No: Suresh S. Ramalingam, MD
  • 08.20 New directions in targeted therapy for advanced NSCLC
    Fadlo R. Khuri, MD, FACP
  • 08.45 Immunotherapy for advanced NSCLC: The present and the future
    Suresh S. Ramalingam, MD
  • 09.10 Small cell lung cancer: Emerging novel options
    Taofeek Owonikoko, MD, PhD
  • 09.35 Debate 2—The case for concurrent therapy for advanced larynx cancer
    Yes: Jonathan Beitler, MD, MBA, FACR, FASTRO
    No: Nabil Saba, MD, FACP
  • 10.00 BREAK
  • 10.25 Combined-modality treatment of stage III disease: How to overcome the plateau?
    Walter Curran, Jr, MD, FACR
  • 10.50 Emerging treatment options for advanced head and neck cancer
    Nabil Saba, MD, FACP
  • 11.15 Debate 3—Molecular markers do not impact therapy choice for diffuse large B-cell lymphoma
    Pro: Christopher Flowers, MD, MS
    Con: Jonathon Cohen, MD, MS
  • 11.40 New treatments for relapsed CLL
    Susan O’Brien, MD
  • 12.05 Immunotherapy for Hodgkin lymphoma, non-Hodgkin lymphoma, and chronic lymphocytic leukemia
    Jonathon Cohen, MD, MS
  • 12.30 LUNCH
  • 12.50 CAR-Ts, BiTEs, DARTs, Oh My! New immune-based treatments
    Amelia Langston, MD
  • 1.15 Navigating treatment in Waldenström macroglobulinemia
    Leonard T. Heffner, Jr, MD
  • 1.40 A review of next generation sequencing in acute myeloid leukemia (AML) and myelodysplastic syndrome
    Anand Jillella, MD
  • 2.05 Challenging cases/panel discussion in lung cancer, head and neck cancer, and lymphoma
  • 2.45 Adjourn

Friday    Gastrointestinal Cancers/Multiple Myeloma/Leukemia


  • 07.30 Debate 1—Should patients with resectable pancreatic cancer receive preoperative chemotherapy?
    Yes: Bassel El-Rayes, MD
    No: David Kooby, MD, FACS
  • 07.55 Expanding options for metastatic pancreatic cancer
    Olatunji Alese, MD
  • 08.20 Immune checkpoint inhibitors in gastrointestinal malignancies
    Bassel El-Rayes, MD
  • 08.45 Management of liver metastases in pancreatic neuroendocrine tumors and colon cancer
    Juan Sarmiento, MD, FACS
  • 09.10 How I treat metastatic colon cancer
    Bert O’Neil, MD
  • 09.35 Role of hyperthermic intraperitoneal chemotherapy
    Charles Staley, MD
  • 10.00 BREAK
  • 10.25 Neuroendocrine cancer: Present therapy and emerging options
    Bassel El-Rayes, MD
  • 10.50 Debate 2—When to treat relapse for myeloma
    Biochemical relapse: Ajay K. Nooka, MD, MPH, FACP
    Symptomatic relapse: Jonathan Kaufman, MD
  • 11.15 New data in relapsed and refractory myeloma
    Ken Anderson, MD
  • 11.40 Induction therapy for myeloma
    Sagar Lonial, MD, FACP
  • 12.05 Practical management of myeloproliferative disorders
    Elliott Winton, MD
  • 12.30 LUNCH
  • 12.50 Debate 3—Treatment of young adults with acute lymphocytic leukemia (ALL): HCVAD or pediatric regimen?
    HCVAD: Hagop Kantarjian, MD
    Pediatric regimen: Leonard T. Heffner, Jr, MD
  • 1.15 New targets and drugs for AML
    Martha Arellano, MD
  • 1.40 Risk and new treatments for ALL
    Leonard T. Heffner, Jr, MD
  • 2.05 Chronic myeloid leukemia: Treatment discontinuation and cure?
    H. Jean Khoury, MD, FACP
  • 2.30 Challenging cases and panel discussion in gastrointestinal tumors, multiple myeloma, and leukemia
  • 3.00 Adjourn

Saturday, July 30    Breast Cancer/Melanoma/Genitourinary/Other Hematology Topics


  • 07.30 Debate 1:—Anthracycline should be omitted in the treatment of early stage HER2/neu- positive breast cancer
    Yes: Elisavet Paplomata, MD
    No: Keerthi Gogineni, MD, MSHP
  • 07.55 Immune checkpoint inhibitors in breast cancer
    Jane Meisel, MD
  • 08.20 Debate 2—All women with early-stage, hormone receptor–positive breast cancer should be treated with adjuvant bisphosphonates or RANK-ligand inhibitors
    Yes: Jane Meisel, MD
    No: Keerthi Gogineni, MD, MSHP
  • 08.45 Management of axilla after systemic neoadjuvant therapy
    Mylin Torres, MD
  • 09.10 Management of ductal carcinoma in situ
    Cletus Arciero, MD, FACS
  • 09.35 BREAK
  • 10.00 Debate 3—Patients with stage III melanoma should be treated with adjuvant ipilimumab
    Yes: Ragini Kudchadkar, MD No: David Lawson, MD
  • 10.25 Treatment of rare cutaneous neoplasms: Uveal melanoma, Merkel cell carcinoma
    Ragini Kudchadkar, MD
  • 10.50 Treatment of metastatic melanoma
    Melinda Yushak, MD, MPH
  • 11.15 Ovarian cancer: Local and systemic therapy
    Ira Horowitz, MD, SM, FACOG, FACS
  • 11.40 Treatment of sarcoma: State of the art
    Melinda Yushak, MD, MPH
  • 12.05 New treatments for relapsed CLL
    James Armitage, MD, FASCO
  • 12.30 LUNCH
  • 12.55 Debate 4:—Patients with standard-risk CLL should receive FCR
    Yes: Susan O’Brien, MD
    No: Jonathon Cohen, MD, MS
  • 1.20 T-cell lymphomas: Sequencing and new agents
    Mary Jo Lechowicz, MD
  • 1.45 Who, what, and when to embark on a thrombophilia workup
    Manila Gaddh, MD
  • 2.10 Challenging cases in genitourinary and breast cancer
  • 2.45 Adjourn

Sunday    Melanoma/Other tumor types


  • 07.30 Debate 1—Active surveillance is acceptable for high-risk prostate cancer
    Sure: Viraj Master, MD, PhD, FACS
    No way: Ashesh Jani, MD, MSEE
  • 07.55 Immune checkpoint inhibitors and other advances in bladder cancer
    Bradley Carthon, MD, PhD
  • 08.20 Advances in treatment of metastatic prostate cancer
    Mehmet Bilen, MD
  • 08.45 Renal cell cancer: Optimal sequencing of systemic therapy
    Michael Atkins, MD
  • 09.10 Incorporating the direct oral anticoagulants into clinical practice
    Christine Kempton, MD, MSc
  • 09.35 Brain tumors: Systemic therapy state of the art
    Ian Crocker, MD, FACR
  • 10.00 Local therapy for primary brain tumors and metastasis
    Ian Crocker, MD, FACR
  • 10.25 Adjourn

Exhibitor Package

The exhibit fee will allow one 6’ exhibit table and complimentary registration, including meals, for two company representatives for all four days of the conference. Additional company representatives may register separately. Exhibit set up will be on Wednesday evening and should remain in place for the duration of the meeting. Attendees will have the opportunity to visit the exhibits during breakfast each morning, at the morning breaks, and before and after the lunch session.


Standard Exhibit Fee: $5000
Premier Placement Exhibit Fee: $7500
Additional representatives may attend for $800 a person ($1000 after May 22)

Registration

Online registration is available at www.winshipcancerDDHO.com. The name and email addresses of both representatives attending are required fields. Payment can be made by check or online by credit card.


PLEASE NOTE: If you choose to pay online via credit card, you will incur a 4.95% processing fee.


For payment by check, please make checks payable to prIME Oncology, LLC
Tax ID # 20-5392799 for the designated amount and send by overnight mail to:

prIME Oncology
Two Concourse Parkway, Suite 260
Atlanta, GA 30328
Attention: Amy Bugg - DDHO


Download Forms

Exhibitor Letter of Request
Agenda - Available Soon
prIME W-9
Premier Exhibitor Letter of Agreement (LOA)
Standard Exhibitor Letter of Agreement (LOA)

We look forward to having your company represented. Should you have any questions or need further information, please feel free to contact Amy Bugg at 678.942.0181 or by email at .

Shipping Materials to The Cloister

Please clearly label items as follows:
Your Name and Company Name
c/o Lori Pratt
100 Cloister Drive
Sea Island, GA 31561
ATTN: Emory Winship DDHO and Jaye Harden, July 27-31, 2016


  • Please number each box in your shipment (eg, “Box 1 of 2,” “Box 2 of 2”)
  • Please bring your own return shipping labels.
  • Each incoming or outgoing package will be charged a handling fee by weight
    1. 0-25 lbs – $10.00
    2. 26-50 lbs – $20.00
    3. 51-100 lbs – $50.00
    4. Over 100 lbs – $100.00

These charges are in addition to actual freight cost.


Lori Pratt, Conference Services Manager at The Cloister, can provide additional information on shipping or any other questions that you might have about the resort:

Download Slides


Thursday, July 28

0730a – Primer on Immune Treatments and Mechanisms - Rathi Pillai, MD
0755a – Should PD-L1 testing be used to select patients for immunotherapy in advanced NSCLC? Yes - Rathi Pillai, MD
0755a – Should PD-L1 testing be used to select patients for immunotherapy in advanced NSCLC? No - Suresh S. Ramalingam, MDD
0820a – New directions in targeted therapy for advanced lung cancer - Fadlo R. Khuri, MD, FACP
0845a – Immunotherapy for advanced NSCLC: The present and the future - Suresh S. Ramalingam, MD
0910a – Small cell lung cancer: Emerging novel options Taofeek Owonikoko, MD, PhD
0935a – Debate 2—The case for concurrent therapy for advanced larynx cancer Yes: Jonathan Beitler, MD, MBA, FACR, FASTRO
0935a – Debate 2—The case for concurrent therapy for advanced larynx cancer No: Nabil Saba, MD, FACP
1025a – Combined-modality treatment of stage III disease: How to overcome the plateau? - Walter Curran, Jr, MD, FACR
1050a – Emerging treatment options for advanced head and neck cancer - Nabil Saba, MD, FACP
1115a – Debate 3—Molecular markers do not impact therapy choice for diffuse large B-cell lymphoma - Pro: Christopher Flowers, MD, MSP
1115a – Debate 3—Molecular markers do not impact therapy choice for diffuse large B-cell lymphoma - Con: Jonathon Cohen, MD, MS
1140a – New treatments for relapsed CLL Susan O’Brien, MD
1205p – Role of Immunotherapy in Lymphomas - Jonathon B. Cohen, MD
1250p – CAR-Ts, BiTEs, DARTs, Oh My! New immune-based treatments Amelia Langston, MD
1315p – Navigating treatment in Waldenström macroglobulinemia - Leonard T. Heffner, Jr, MD
1340p – A review of next generation sequencing in acute myeloid leukemia (AML) and myelodysplastic syndrome - Anand Jillella, MD

Friday, July 29

0730a - Debate 1—Should patients with resectable pancreatic cancer receive preoperative chemotherapy? Yes: Bassel El-Rayes, MD
0730a - Debate 1—Should patients with resectable pancreatic cancer receive preoperative chemotherapy? No: David Kooby, MD, FACS
0755a - Expanding options for metastatic pancreatic cancer - Olatunji Alese, MD
0820a - Immune checkpoint inhibitors in gastrointestinal malignancies - Bassel El-Rayes, MD
0845a - Management of liver metastases in pancreatic neuroendocrine tumors and colon cancer - Juan Sarmiento, MD, FACS
0910a - How I treat metastatic colon cancer - Bert O’Neil, MD
0935a - Role of hyperthermic intraperitoneal chemotherapy - Charles Staley, MD
1025a - Neuroendocrine cancer: Present therapy and emerging options - Bassel El-Rayes, MD
1050a - Debate 2—When to treat relapse for myeloma - Biochemical relapse: Ajay K. Nooka, MD, MPH, FACP
1050a - Debate 2—When to treat relapse for myeloma - Symptomatic relapse: Jonathan Kaufman, MD
1115a - New data in relapsed and refractory myeloma - Ken Anderson, MD
1140a - Induction therapy for myeloma - Sagar Lonial, MD, FACP
1205p - Practical management of myeloproliferative disorders - Elliott Winton, MD
1250p - Debate 3—Treatment of young adults with acute lymphocytic leukemia (ALL): HCVAD or pediatric regimen? HCVAD: Hagop Kantarjian, MD
1250p - Debate 3—Treatment of young adults with acute lymphocytic leukemia (ALL): HCVAD or pediatric regimen? Pediatric regimen: Leonard T. Heffner, Jr, MD
0115p - New targets and drugs for AML - Martha Arellano, MD
0205p - Chronic myeloid leukemia: Treatment discontinuation and cure? - H. Jean Khoury, MD, FACP

Saturday, July 30

0730a - Debate 1:—Anthracycline should be omitted in the treatment of early stage HER2/neu- positive breast cancer - Yes: Elisavet Paplomata, MD
0730a - Debate 1:—Anthracycline should be omitted in the treatment of early stage HER2/neu- positive breast cancer - No: Keerthi Gogineni, MD, MSHP
0755a - Immune checkpoint inhibitors in breast cancer - Jane Meisel, MD
0820a - Debate 2—All women with early-stage, hormone receptor–positive breast cancer should be treated with adjuvant bisphosphonates or RANK-ligand inhibitors - Yes: Jane Meisel, MD
0820a - Debate 2—All women with early-stage, hormone receptor–positive breast cancer should be treated with adjuvant bisphosphonates or RANK-ligand inhibitors - No: Keerthi Gogineni, MD, MSHP
0845a - Management of axilla after systemic neoadjuvant therapy - Mylin Torres, MD
0910a - Management of ductal carcinoma in situ - Cletus Arciero, MD, FACS
1000a - Debate 3—Patients with stage III melanoma should be treated with adjuvant ipilimumab - Yes: Ragini Kudchadkar, MD
1000a - Debate 3—Patients with stage III melanoma should be treated with adjuvant ipilimumab - No: David Lawson, MD
1025a - Treatment of rare cutaneous neoplasms: Uveal melanoma, Merkel cell carcinoma Ragini Kudchadkar, MD
1050a - Treatment of metastatic melanoma - Melinda Yushak, MD, MPH
1115a - Ovarian cancer: Local and systemic therapy - Ira Horowitz, MD, SM, FACOG, FACSH
1140a - Treatment of sarcoma: State of the art - Melinda Yushak, MD, MPH
1205p - New treatments for relapsed CLL James Armitage, MD, FASCO
1255p - Debate 4:—Patients with standard-risk CLL should receive FCR - Yes: Susan O’Brien, MD
1255p - Debate 4:—Patients with standard-risk CLL should receive FCR - No: Jonathon Cohen, MD, MS
0120p - T-cell lymphomas: Sequencing and new agents - Mary Jo Lechowicz, MD
0145p - Who, what, and when to embark on a thrombophilia workup - Manila Gaddh, MD

Sunday, July 31

0730a - Debate 1—Active surveillance is acceptable for high-risk prostate cancer - Sure: Viraj Master, MD, PhD, FACS
0730a - Debate 1—Active surveillance is acceptable for high-risk prostate cancer - No way: Ashesh Jani, MD, MSEE
0755a - Immune checkpoint inhibitors and other advances in bladder cancer - Bradley Carthon, MD, PhD
0820a - Advances in treatment of metastatic prostate cancer Mehmet Bilen, MD
0845a - Renal cell cancer: Optimal sequencing of systemic therapy - Michael Atkins, MD
0910a - Incorporating the direct oral anticoagulants into clinical practice - Christine Kempton, MD, MSc
0935a - Brain tumors: Systemic therapy state of the art - Ian Crocker, MD, FACR